SAN FRANCISCO — To move forward successfully, venture capitalists interested in eye care need to be prepared to support longer development cycles, according to a speaker here.
“When you look at the ophthalmology index as a whole, whether it’s pharma or device, there is a lot of market cap that is consolidated amongst a handful of names. It’s not spread out,” Andrew Gitkin, vice chairman of health care investment banking at Raymond James, said at Eyecelerator@AAO. “Moving some of these names can have a significant impact on the index.”
While delivering a